FOXO Technologies (FOXO)’ Board of Directors has approved pursuing the spin-off of its FOXO Labs subsidiary that is focused on the development of its epigenetics business The Epigenetics subsidiary has been serving as a pioneer in the development and integration of epigenetic biomarkers into underwriting protocols and consumer engagement tools and owns Patent No. 11,817,214 titled “Machine Learning Model Trained to Determine a Biochemical State and/or Medical Condition Using DNA Epigenetic Data. Epigenetic technology has been proven to provide health, lifestyle, and longevity insights that have never before been accessible to humans-from just a single saliva sample. Using saliva-based epigenetic biomarkers, we’re eliminating the need for invasive blood and urine collection, allowing us to provide scientists with advanced epigenetic testing services and bioinformatics tools that support ground-breaking research.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOXO:
- FOXO Technologies Announces Reverse Stock Split
- Foxo Technologies authorizes 1 for 1.99 reverse stock split
- FOXO Technologies Secures Second Year of Opioid Funding
- Foxo’s Myrtle Recovery Centers approved for Scott County Opioid Abatement Funds
- FOXO Technologies Announces New Series E Preferred Stock